A magnifying glass. It indicates, "Click to perform a search". A magnifying glass. It indicates, "Click to perform a search". CATANIA, Italy, Oct. 13, 2022 /PRNewswire/ -- SIFI S.p.A (SIFI or "the ...

Please provide your email address to receive an email when new articles are posted on . The authorization is supported by positive data from a phase 3 pivotal trial. Avanzanite Bioscience has ...

ACI SANT'ANTONIO, Italy, May 31, 2024 /PRNewswire/ -- SIFI announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive ...

SIFI S.p.A, a leading international ophthalmic company headquartered in Italy, reported the presentation of positive results from the positive phase 3 study [NCT03274895] of Akantior (polihexanide ...

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has backed approval for Akantior (polihexanide), a potential first medicine to treat acanthamoeba keratitis.

AKANTIOR® is slated to become the first approved orphan medicinal product for acanthamoeba keratitis after more than 15 years of eye disease research conducted by SIFI SIFI reaffirms guidance of ...

ACI SANT'ANTONIO, Italy, May 31, 2024 /PRNewswire/ -- SIFI announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive ...

The CHMP recommendation will now be reviewed by the European Commission (EC), which may decide on the marketing authorisation (MA) for AKANTIOR ® in August 2024. The decision will then be applicable ...